AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 75(1), 2006, pp. 26-28
Copyright © 2006 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHANTHAVANICH, P.
Right arrow Articles by LANG, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CHANTHAVANICH, P.
Right arrow Articles by LANG, J.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Dengue
Related Collections
Right arrow Vaccine
Right arrow Dengue

SHORT REPORT


IMMUNE RESPONSE AND OCCURRENCE OF DENGUE INFECTION IN THAI CHILDREN THREE TO EIGHT YEARS AFTER VACCINATION WITH LIVE ATTENUATED TETRAVALENT DENGUE VACCINE

PORNTHEP CHANTHAVANICH, CHRISTINE LUXEMBURGER*, CHUKIAT SIRIVICHAYAKUL, KESWADEE LAPPHRA, KRISANA PENGSAA, SUTEE YOKSAN, ARUNEE SABCHAREON, AND JEAN LANG
Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sanofi Pasteur, Lyon, France; Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, Nakhonpathom, Thailand

 

ABSTRACT

From 1992 to 1997, 140 Thai children 4–15 years of age received an investigational live attenuated tetravalent dengue vaccine (LATDV). These children were contacted 3–8 years later in 2001 to assess humoral immunity and investigate whether they were subsequently at higher risk of developing severe dengue. One hundred thirteen were successfully contacted and participated in this retrospective cohort study with two age- and address-matched controls per vaccinee. The number of vaccinated subjects with neutralizing antibodies increased compared with 3–8 years earlier, which was probably due to subsequent wild-type dengue infections. There were no excess hospitalizations for clinically suspected dengue fever (DF) or dengue hemorrhagic fever (DHF) in vaccinees (one with DF and three with DHF) compared with controls (14 with DHF). Results suggest that preexisting dengue antibodies induced by LATDV do not enhance dengue illness, and the use of the vaccine in a dengue-endemic area is safe.

Received August 2, 2005. Accepted for publication March 23, 2006.

Acknowledgments: We thank Tanit Tapanasoot (Head of Plang-Yao Health Center) for help in the follow-up of vaccinated cases, N. Braham for help in the statistical analysis, and G. Marsh for his assistance in drafting the manuscript. We also thank all volunteers who participated in this study.

Financial support: This study was supported by a grant from Sanofi Pasteur.

* Address correspondence to Christine Luxemburger, Sanofi Pasteur, 2 Avenue Pont Pasteur, 69367 Lyon, France. E-mail: christine.luxemburger{at}sanofipasteur.com

Authors’ addresses: Pornthep Chanthavanich, Chukiat Sirivichayakul, Keswadee Lapphra, Krisana Pengsaa, and Arunee Sabchareon, Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchadewee, Bangkok 10400, Thailand. Christine Luxemburger, Sanofi Pasteur, 2 Avenue Pont Pasteur, 69367 Lyon, France, Telephone: 33-4-3737-7612, E-mail: christine.luxemburger{at}sanofipasteur.com. Sutee Yoksan, Centre for Vaccine Development, Institute of Science and Technology for Research and Development, Mahidol University at Salaya, 25/25 Salaya, Phuttamonthon District, Nakhon Pathom Province 73170, Thailand. Jean Lang, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280 Marcy l’Etoile, France.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
B. E. E. Martina, P. Koraka, and A. D. M. E. Osterhaus
Dengue Virus Pathogenesis: an Integrated View
Clin. Microbiol. Rev., October 1, 2009; 22(4): 564 - 581.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Klungthong, R. V. Gibbons, B. Thaisomboonsuk, A. Nisalak, S. Kalayanarooj, V. Thirawuth, N. Nutkumhang, M. P. Mammen Jr., and R. G. Jarman
Dengue Virus Detection Using Whole Blood for Reverse Transcriptase PCR and Virus Isolation
J. Clin. Microbiol., August 1, 2007; 45(8): 2480 - 2485.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Tropical Medicine and Hygiene.